{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:31:17Z","timestamp":1760059877501,"version":"build-2065373602"},"reference-count":15,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL), have been associated with the development of Guillain\u2013Barr\u00e9 syndrome (GBS). Specifically, treatment with the immunomodulator rituximab, which is used in the backbone of DLBCL treatment, has increasingly been used in this patient population. Case Presentation: We present the case of a man in his 60s with DLBCL who presented to the hospital with the progressive weakness of the bilateral upper and lower extremities within 6 weeks of the completion of treatment including rituximab. The temporal relationship between the completion of rituximab and subsequent polyradiculoneuropathy, as well as a favorable response to intravenous immunoglobulin (IVIG), affirmed the diagnosis of treatment-induced GBS. Conclusions: The increased use of rituximab as part of a standard treatment regimen for hematologic malignancies demonstrates the need for an awareness of a possible association between rituximab and the subsequent paradoxical development of GBS, which will allow for expeditious evaluation for better patient outcomes.<\/jats:p>","DOI":"10.3390\/reports8030119","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:02:06Z","timestamp":1753257726000},"page":"119","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Possible Association Between Rituximab and the Subsequent Development of Guillain\u2013Barr\u00e9 Syndrome: A Case Report"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5370-8586","authenticated-orcid":false,"given":"Lilian","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, West Virginia University, Morgantown, WV 26506, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-1505","authenticated-orcid":false,"given":"Stephen Lee","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West Virginia University, Morgantown, WV 26506, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nolan","family":"Holley","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, West Virginia University, Morgantown, WV 26506, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salahuddin","family":"Safi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West Virginia University, Morgantown, WV 26506, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management","volume":"96","author":"Barta","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_2","unstructured":"National Cancer Institute, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"38890","DOI":"10.1097\/MD.0000000000038890","article-title":"Clinical presentation and symptomatology of Guillain-Barr\u00e9 syndrome: A literature review","volume":"30","author":"Elendu","year":"2024","journal-title":"Medicine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1529-8027.2007.00134.x","article-title":"Guillain-Barr\u00e9 syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma","volume":"12","author":"Terenghi","year":"2007","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s12094-006-0126-5","article-title":"Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyound anecdotal evidence?","volume":"8","author":"Carmona","year":"2006","journal-title":"Clin. Transl. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.12998\/wjcc.v10.i26.9502","article-title":"Guillain-Barr\u00e9 syndrome and hemophagocytic syndrome heralding the diagnosis of diffuse large B cell lymphoma: A case report","volume":"10","author":"Zhou","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/jns.12594","article-title":"European Academy of Neurology\/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barre syndrome","volume":"28","author":"Hadden","year":"2023","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain\u2013Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1555","DOI":"10.1212\/WNL.0000000000200015","article-title":"Association between incident cancer and Guillain-Barre syndrome development: A nationwide case-control study","volume":"98","author":"Levison","year":"2022","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/MD.0000000000000394","article-title":"Value of nerve biopsy in patients with latent malignant hemopathy and peripheral neuropathy: A case series","volume":"94","author":"Duchesne","year":"2015","journal-title":"Medicine"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Dabkowska, A., Domka, K., and Firczuk, M. (2024). Advancements in cancer immunotherapies targeting CD20: From pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1363102"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1034\/j.1399-3089.2001.008003157.x","article-title":"Effects of specific anti-B and\/or anti-plasma cell immunotherapy on antibody production in baboons: Depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody","volume":"8","author":"Alwayn","year":"2001","journal-title":"Xenotransplantation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1468-1331.2007.01842.x","article-title":"Vincristine-induced acute neurotoxicity versus Guillain\u2013Barr\u00e9 syndrome: A diagnostic dilemma","volume":"14","author":"Campos","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hartinger, J.M., Kratky, V., Hruskova, Z., Slanar, O., and Tesar, V. (2022). Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1024068"}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/3\/119\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:14:20Z","timestamp":1760033660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/3\/119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["reports8030119"],"URL":"https:\/\/doi.org\/10.3390\/reports8030119","relation":{},"ISSN":["2571-841X"],"issn-type":[{"type":"electronic","value":"2571-841X"}],"subject":[],"published":{"date-parts":[[2025,7,23]]}}}